Open Access

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells

  • Authors:
    • Mai Nakahara
    • Shintaro Fujihara
    • Hisakazu Iwama
    • Kei Takuma
    • Kyoko Oura
    • Tomoko Tadokoro
    • Koji Fujita
    • Joji Tani
    • Asahiro Morishita
    • Hideki Kobara
    • Takashi Himoto
    • Tsutomu Masaki
  • View Affiliations

  • Published online on: August 3, 2022     https://doi.org/10.3892/br.2022.1561
  • Article Number: 78
  • Copyright: © Nakahara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lenvatinib is a tyrosine kinase receptor inhibitor used to treat unresectable hepatocellular carcinoma (HCC). In this study, we investigated the antitumor effects of Lenvatinib treatment on HCC cell lines. Proliferation was examined in four HCC cell lines (HuH‑7, Hep3B, Li‑7, and PLC/PRF/5) using Cell Counting Kit‑8 assays. Xenograft mouse models were used to assess the effects of Lenvatinib in vivo. Cell cycle, western blotting, and microRNA (miRNA) expression analyses were performed to identify the antitumor inhibitory potential of Lenvatinib on HCC cells. Lenvatinib treatment suppressed proliferation of HuH‑7 and Hep3B, but not Li‑7 and PLC/PRF/5 cells and induced G0/G1 cell cycle arrest and cyclin D1 downregulation in Lenvatinib‑sensitive cells. Lenvatinib treatment also reduced tumor growth in HuH‑7 xenograft mouse models. miRNA microarrays revealed that Lenvatinib treatment altered the expression of miRNAs in HuH7 cells and exosomes. Our results demonstrated the therapeutic potential of Lenvatinib and provide molecular mechanistic insights into its antitumor effects for treating HCC.

Related Articles

Journal Cover

October-2022
Volume 17 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakahara M, Fujihara S, Iwama H, Takuma K, Oura K, Tadokoro T, Fujita K, Tani J, Morishita A, Kobara H, Kobara H, et al: Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells. Biomed Rep 17: 78, 2022
APA
Nakahara, M., Fujihara, S., Iwama, H., Takuma, K., Oura, K., Tadokoro, T. ... Masaki, T. (2022). Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells. Biomedical Reports, 17, 78. https://doi.org/10.3892/br.2022.1561
MLA
Nakahara, M., Fujihara, S., Iwama, H., Takuma, K., Oura, K., Tadokoro, T., Fujita, K., Tani, J., Morishita, A., Kobara, H., Himoto, T., Masaki, T."Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells". Biomedical Reports 17.4 (2022): 78.
Chicago
Nakahara, M., Fujihara, S., Iwama, H., Takuma, K., Oura, K., Tadokoro, T., Fujita, K., Tani, J., Morishita, A., Kobara, H., Himoto, T., Masaki, T."Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells". Biomedical Reports 17, no. 4 (2022): 78. https://doi.org/10.3892/br.2022.1561